Word: journals
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Quality journalism is not cheap, and an industry that gives away its content is simply cannibalizing its ability to produce good reporting," Murdoch said during a call with analysts and reporters. The Wall Street Journal, which he owns, is one of the very few news operations to charge users to see its content online. Now he wants to put all his sites - News Corp. is the biggest producer of news in the English-speaking world - behind a pay wall. That includes the online output of papers that run the spectrum of quality all the way from the snobby Times...
...experimental drug has successfully reduced hip and spine fractures in the two largest patient populations at risk for osteoporosis - postmenopausal women and men being treated for prostate cancer - according to two major studies published online on Aug. 11 by the New England Journal of Medicine. The new compound, denosumab, is being reviewed by the Food and Drug Administration. If approved, it has the potential to become a standard treatment for certain patients...
...second trial published in the New England Journal of Medicine included 7,868 postmenopausal women between the ages of 60 and 90, who were also given either a placebo or injections of denosumab every six months for 36 months. Compared with the placebo group, the treated patients in this study had a 68% lower risk of vertebral fracture and a 40% lower risk of hip fracture over three years. Overall, 2.3% of women receiving denosumab had a spine fracture and 0.7% had a hip fracture, compared with 7.2% and 1.2% in the placebo group, respectively. (Read "Osteoarthritis: Not Just...
...much impact this would have on patient care remains to be seen," says Dr. Sundeep Khosla, a professor of medicine at the Mayo Clinic, who wrote an editorial accompanying the two studies in the Journal. But because denosumab did not result in any serious side effects, it has the potential of becoming a safer alternative, should its current profile hold up in additional studies...
...Khosla notes that neither the bisphosphonates nor denosumab actually causes the creation of new bone, which would be the ultimate goal of any osteoporosis treatment. The increases in bone-mineral density seen in the Journal studies is primarily due to minerals filling in the gaps left in the wake of bone destruction, he says. "In my mind, the dramatic changes will be seen with the anabolic agents," he says. "They hold the potential for completely curing the disease, reversing bone loss so you effectively are not osteoporotic any more...